source
- Pharma deals in China face heightened IP risk under U.S. BIOSECURE ActPharma companies are increasing licensing activity in China, but experts say patent attorneys must now factor in the geopolitical implications of the BIOSECURE Act. The legislation seeks to compil…
- Boston Scientific launches multi-year restructuring plan, foresees $500 million annual savings and job cutsBoston Scientific announced a global restructuring program that will run from this year through 2029, aiming to streamline its supply chain and reorganize functions. The plan involves moving certa…